- Powered by its strong earnings growth of 37.14% and other important driving factors, this stock has surged by 50.73% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
- GRIFOLS SA has improved earnings per share by 37.1% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, GRIFOLS SA increased its bottom line by earning $1.39 versus $0.96 in the prior year. This year, the market expects an improvement in earnings ($2.64 versus $1.39).
- The gross profit margin for GRIFOLS SA is rather high; currently it is at 55.19%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, GRFS's net profit margin of 15.15% significantly trails the industry average.
- Currently the debt-to-equity ratio of 1.72 is quite high overall and when compared to the industry average, suggesting that the current management of debt levels should be re-evaluated. Regardless of the company's weak debt-to-equity ratio, GRFS has managed to keep a strong quick ratio of 1.85, which demonstrates the ability to cover short-term cash needs.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Health Care sector as a whole closed the day down 2.3% versus the S&P 500, which was down 0.5%. Laggards within the Health Care sector included Aoxing Pharmaceutical ( AXN), down 4.5%, Reliv' International ( RELV), down 1.8%, Pro-Dex ( PDEX), down 2.3%, Bio-Rad Laboratories ( BIO.B), down 1.6% and Neovasc ( NVCN), down 2.0%. TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today: Grifols ( GRFS) is one of the companies that pushed the Health Care sector lower today. Grifols was down $1.51 (3.5%) to $42.18 on average volume. Throughout the day, 560,387 shares of Grifols exchanged hands as compared to its average daily volume of 670,000 shares. The stock ranged in price between $42.12-$43.85 after having opened the day at $43.85 as compared to the previous trading day's close of $43.69. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $15.0 billion and is part of the drugs industry. Shares are up 21.0% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Highlights from TheStreet Ratings analysis on GRFS go as follows: